Navigation Links
New TB Vaccine Passes Safety Trial
Date:4/8/2009

Experimental preparation was tested in people with latent infection,,

WEDNESDAY, April 8 (HealthDay News) -- An experimental tuberculosis vaccine called MVA85A proved safe in a small phase I clinical trial.

The study included 12 people with latent tuberculosis infection, which, when re-activated, can cause full-blown TB. It's believed that about a third of the world's population has this latent infection. The participants, who had no other complicating factors, such as hepatitis or HIV, were given the vaccine and then followed for a year.

The researchers concluded that the vaccine was safe, did not produce any immunopathology and was immunogenic in the patients. Some participants had side effects that included fever, headache, fatigue and mild concerns at the site of the vaccination.

The findings appear in the April 15 issue of the American Journal of Respiratory and Critical Care Medicine.

This study could be an important step forward in efforts to introduce a new vaccine to fight TB, according to the researchers, led by Dr. Helen McShane, of the University of Oxford in England. They noted that any new vaccine must be developed with latent TB infection in mind because it might decrease the effectiveness of new vaccines or worsen vaccine-related side effects.

"A more effective vaccine regimen than the currently available bacillus Calmette-Guerin would have a major impact on the global TB burden and, ultimately, will be the most efficient way to control this pandemic," the researchers wrote.

They noted that larger trials of the vaccine "are needed in TB endemic areas to assess the efficacy of this vaccine against the development of TB disease, but these results are very encouraging and justify the further development of this vaccine."

More information

The American Lung Association has more about TB.



-- Robert Preidt



SOURCE: American Thoracic Society, news release, April 7, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Dieter Luetticken Award 2008 Recognizes Development of New Vaccine Quality Control Assay
2. Hard To Treat Diseases (HTDS) Offers Hepatitis A Vaccine in India
3. U.S. Adults Needlessly Vulnerable to Vaccine-Preventable Diseases, According to New Report
4. Intercell Announces FDA Approval of IXIARO(R), a Vaccine Against Japanese Encephalitis
5. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
6. Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
7. Oral Yogurt Vaccine Could Blunt Ouch Factor
8. HPV Data May Aid Vaccines Effectiveness
9. Saving Vaccines with SensoTech's Breakthrough in Vaccine Temperature Monitoring
10. HARD TO TREAT DISEASES (HTDS) Influenca Vaccine (MEVAC-FLU) Enters Chilean Market
11. TB vaccine developed at McMaster University in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New TB Vaccine Passes Safety Trial
(Date:4/24/2017)... ... April 24, 2017 , ... Salus Telehealth, ... the company’s VideoMedicine mobile platform has launched Quick Care, a new service offering ... Quick Care provides patients with the option to request and begin a consultation ...
(Date:4/24/2017)... ... 24, 2017 , ... MAP Health Management announced today a ... with addiction who are served by MAP’s patient engagement ecosystem. Lief Therapeutics is ... heart and breath rates to identify anxiety levels and can provide biofeedback exercises ...
(Date:4/24/2017)... NJ (PRWEB) , ... April 24, 2017 , ... Come ... Plaza Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. ... of our staff hearing this before they approach patients” about the course entitled Ain't ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each person ... author, Jerri Broglin, a survivor of great loss who gained insight on how to ... those searching for answers, as we are finding the answers that are so deep ...
(Date:4/24/2017)... ... April 24, 2017 , ... Life of Purpose Treatment is proud ... event will be held at 7:30 pm on May 10th at the University Auditorium. ... of Sister Hazel, will support the UF Collegiate Recovery Community (UFCRC). The concert will ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Companion animal ... in pets such as canine, avian and feline. ... types such as Attenuated Live Vaccines, Conjugate Vaccines, ... and Recombinant Vaccines. Attenuated live vaccines are derived ... which have been weakend under laboratory conditions. Conjugate ...
(Date:4/18/2017)... 18, 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), ... Urology, Uro/Gyn and Gynecology markets with innovative and proprietary ... ended March 31, 2017 after the market close on ... will host a conference call and webcast to discuss ... 2, 2017 at 4:30 p.m. Eastern Time (3:30 p.m. ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc. and ... started in 2016, in which Socionext extracts and ... The companies achieved initial results in reading ultrasound ... Artificial Brain SOINN. The results will be introduced ... April 19-21, at booths 4505 & 4507. ...
Breaking Medicine Technology: